AgroSavfe Raises €35M to Develop Eco-Friendly Pesticides
The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The
Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and Brain
Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced initiation of a Phase 1 open label clinical trial to establish the safety of
Hesperos Human-on-a-Chip Technology Awarded First Phase of $3.8 Million Milestone-based NIH Grant to Study Opiate Overdoses
Hesperos Inc. announced the University of Central Florida (UCF) and Hesperos have received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. The goal of the research is
Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism
A vaccine developed by the Danish company Bavarian Nordic has received FDA approval to prevent infections by monkeypox, as well as protect against the threat of a smallpox bioterror attack. This approval makes Bavarian Nordic’s vaccine the only approved vaccine in
Lab-Grown Skin as Good as Skin Grafts for Burns at Phase III
Mallinckrodt’s treatment made of artificial skin tissue called Stratagraft closed over 80% of second-degree burn wounds in a phase III trial, matching the effectiveness of skin grafts. Mallinckrodt recruited 71 patients with second-degree burns who were eligible for skin grafts into
AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I
AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which
HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing
HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing, Consisting of $19.0 Million Public Offering of Common Stock, Including the Exercise in Full of the Underwriter’s Option to Purchase Additional Shares, and $3.5 Million Concurrent Private Placement. HTG is focused
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life
Sexton Biotechnologies Raises $5M to Accelerate Commercialization of Cook Regentec’s Bioproduction Tools
Sexton Biotechnologies announced that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research
Varian buys software developer for AI cancer work
Varian said it is investing in privately held Oncora Medical and will partner with the software company to develop machine learning-guided decision support tools. The aim is to help doctors create personalized treatment plans for cancer patients. Financial terms weren't